Hepatitis/MASH

A recent FDA study determined that current nucleic acid testing (NAT) of the plasma of donated blood is adequate for the detection of the hepatitis C virus (HCV).

Testing baby boomers could help identify more than 800,000 new cases of hepatitis C and address the largely preventable consequences of the condition.

Testing this sample of the population could help identify more than 800,000 new cases of hepatitis C and address the largely preventable consequences of the condition.

New triple-therapy regimens for hepatitis C are expensive, but they can be cost-effective for many patients.

Could treatment for hepatitis C viral infection become an all-oral supplement?

Organs and tissue donated by a Kentucky man infected with the hepatitis C virus causes disease transmission to multiple organ recipients.

The Department of Health and Human Services action plan calls for better strategies and methods of treating and diagnosing viral hepatitis.

With an all-oral combination therapy and a hepatitis C vaccine on the horizon, pharmacists and patients will soon have new resources against this prevalent infection.

The FDA sent out a "Drug Safety Communication" from their Division of Drug Information on February 9, 2012, listing the important new drug interactions between Victrelis (boceprevir) and ritonavir-boosted HIV protease inhibitor drugs.

New guidelines for the human papillomavirus and hepatitis B vaccines impact young boys and elderly patients with diabetes.

Adherence for targeted therapies is even more essential now than it ever has been. This case study of services offered at a specialty pharmacy illustrates the impact of hepatitis C patients.

Pharmacies in the community setting have led the way in patient compliance, but have been largely ignored by MCOs and the pharmaceutical industry.

Findings from a new study point to the need for interventions to help patients take medications properly and manage their disease more effectively.

Adherence for targeted therapies is even more essential now than it ever has been. This case case studies of services offered at a specialty pharmacy illustrates the impact of hepatitis C patients.

Back pain is often preventable, but when it strikes, there are many products that promise relief, including pills, patches, belts, compresses, and topical treatments.

Researchers assess new study models and investigate triple drug therapies to fight hepatitis C infection.

Hepatitis C can be a challenging disease for patients. Pharmacists can be instrumental in educating their patients about the pharmacologic agents available for treatment and provide them with valuable resources to successfully manage this condition.